Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Bhatt, Hasan; Szarek, Michael; Pitt, Bertram; Cannon, Christopher; Leiter, Lawrence; McGuire, Darren; Lewis, Julia; Riddle, Matthew; Inzucchi, Silvio; Kosiborod, Mikhail; Cherney, David; Dwyer, Jamie; Scirica, Benjamin; Bailey, Clifford; Díaz, Rafael; Ray, Kausik; Udell, Jacob; Lopes, Renato; Lapuerta, Pablo; Steg, P

doi:10.1056/nejmoa2030186

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Bhatt D. L., Szarek M., Pitt B., Cannon C. P., Leiter L. A., McGuire D. K., ...More

The New England journal of medicine, vol.384, pp.129-139, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 384
Publication Date: 2021
Doi Number: 10.1056/nejmoa2030186
Journal Name: The New England journal of medicine
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Page Numbers: pp.129-139
Istanbul University Affiliated: Yes

Abstract

In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin.